| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 6, 2024 | Dicot presents interim report Q1 2024 | Dicot presents interim report Q1 2024
Mon, May 06, 2024 07:50 CET Report this content
Press release: Uppsala, Sweden, May 6, 2024. Dicot AB (publ) publishes its interim report for the first quarter 2024. The report is available as an attach... |
| Apr 23, 2024 | Good safety and improved erectile function reported from Dicot’s phase 1 study | Good safety and improved erectile function reported from Dicot’s phase 1 study
Tue, Apr 23, 2024 18:10 CET Report this content
Press release: Uppsala, April 23, 2024. Dicot's completed phase 1 clinical study demonstrates that the company's ... |
| Apr 12, 2024 | Dicot in preparation for clinical phase 2a trial | Dicot in preparation for clinical phase 2a trial
Fri, Apr 12, 2024 08:30 CET Report this content
Press release: Uppsala, Sweden, April 12, 2024. The pharmaceutical company Dicot, which recently announced that a reporting from the last part ... |
| Apr 5, 2024 | Reporting from Dicot's phase 1 study end of April | Reporting from Dicot's phase 1 study end of April
Fri, Apr 05, 2024 08:30 CET Report this content
Press release: Uppsala, April 5, 2024. Yesterday, Dicot completed the clinical phase of the second and final part of its phase 1 study. The co... |
| Mar 11, 2024 | Recruitment completed in Dicot’s phase 1 trial | Recruitment completed in Dicot’s phase 1 trial
Mon, Mar 11, 2024 08:30 CET Report this content
Press release: Uppsala, Sweden, March 11, 2024. Today, the potency drug developer Dicot announces that the recruitment to the final part of its p... |
| Feb 26, 2024 | Dicot AB Year-End Report 2023 | Dicot AB Year-End Report 2023
Mon, Feb 26, 2024 15:00 CET Report this content
Press release: Uppsala, Sweden, February 26, 2024. Dicot AB (publ) publishes its year-end report for the financial year 2023 and for the fourth quarter. The year-... |
| Jan 23, 2024 | Positive results from the first part of Dicot's phase 1 study | Positive results from the first part of Dicot's phase 1 study
Tue, Jan 23, 2024 11:59 CET Report this content
Press release: Uppsala, Sweden, January 23, 2024. Dicot presents positive results from the first part of its phase 1 clinical stud... |
| Jan 11, 2024 | Dicot applies for patent covering new manufacturing technology | Dicot applies for patent covering new manufacturing technology
Thu, Jan 11, 2024 08:45 CET Report this content
Press release: Uppsala, Sweden, January 11, 2024. The pharmaceutical company Dicot has applied for a patent covering a novel tech... |
| Jan 5, 2024 | Dicot invited to present at ESSM for the third time | Dicot invited to present at ESSM for the third time
Fri, Jan 05, 2024 09:53 CET Report this content
Press release: Uppsala, Sweden, January 5, 2024. The pharmaceutical company Dicot's preclinical research results have been selected to be pr... |
| Dec 15, 2023 | Partial results from Dicot's phase 1 trial to be presented early next year | Partial results from Dicot's phase 1 trial to be presented early next year
Fri, Dec 15, 2023 09:00 CET Report this content
Press Release: Uppsala, December 15, 2023. Yesterday, the potency drug developer Dicot concluded the clinical part of... |
| Nov 24, 2023 | Dicot gains significant interest at North America's major sexual medicine congress | Dicot gains significant interest at North America's major sexual medicine congress
Fri, Nov 24, 2023 11:30 CET Report this content
Press release: Uppsala, November 24, 2023. During the fall, the pharmaceutical company Dicot received accepta... |
| Nov 24, 2023 | Dicot gains significant interest at North America's major sexual medicine congress | Dicot gains significant interest at North America's major sexual medicine congress
Fri, Nov 24, 2023 11:30 CET Report this content
Press release: Uppsala, November 24, 2023. During the fall, the pharmaceutical company Dicot received accepta... |
| Nov 17, 2023 | Dicot's warrants of series TO5 subscribed at 85.4%, provides the company 16.5 MSEK before cost | Dicot's warrants of series TO5 subscribed at 85.4%, provides the company 16.5 MSEK before cost
Fri, Nov 17, 2023 10:58 CET Report this content
Press release: Uppsala, Sweden, November 17, 2023. Dicot AB (publ) today announces that the exerc... |
| Nov 17, 2023 | Dicot's warrants of series TO5 subscribed at 85.4%, provides the company 16.5 MSEK before cost | Dicot's warrants of series TO5 subscribed at 85.4%, provides the company 16.5 MSEK before cost
Fri, Nov 17, 2023 10:58 CET Report this content
Press release: Uppsala, Sweden, November 17, 2023. Dicot AB (publ) today announces that the exerc... |
| Nov 14, 2023 | Dicot initiates repeated dosing in its clinical study | Dicot initiates repeated dosing in its clinical study
Tue, Nov 14, 2023 08:00 CET Report this content
Press release: Uppsala, November 14, 2023. The potency drug developer Dicot's phase 1 study is now entering its second and final part. Aft... |
| Nov 14, 2023 | Dicot initiates repeated dosing in its clinical study | Dicot initiates repeated dosing in its clinical study
Tue, Nov 14, 2023 08:00 CET Report this content
Press release: Uppsala, November 14, 2023. The potency drug developer Dicot's phase 1 study is now entering its second and final part. Aft... |
| Nov 2, 2023 | Letters of intent from major owners, directors, and management to subscribe for SEK 4.7 million (24.2%) in Dicot's TO5 which runs until November 15, 2023 | Letters of intent from major owners, directors, and management to subscribe for SEK 4.7 million (24.2%) in Dicot's TO5 which runs until November 15, 2023
Thu, Nov 02, 2023 11:32 CET Report this content
Press release: Uppsala, Sweden, Novemb... |
| Nov 2, 2023 | Letters of intent from major owners, directors, and management to subscribe for SEK 4.7 million (24.2%) in Dicot's TO5 which runs until November 15, 2023 | Letters of intent from major owners, directors, and management to subscribe for SEK 4.7 million (24.2%) in Dicot's TO5 which runs until November 15, 2023
Thu, Nov 02, 2023 11:32 CET Report this content
Press release: Uppsala, Sweden, Novemb... |
| Nov 1, 2023 | The exercise period for warrants TO5 in Dicot starts today | The exercise period for warrants TO5 in Dicot starts today
Wed, Nov 01, 2023 08:00 CET Report this content
Press release: Uppsala, Sweden, November 1, 2023. Today, November 1, 2023, the exercise period for warrants of series TO5 in Dicot AB... |
| Nov 1, 2023 | The exercise period for warrants TO5 in Dicot starts today | The exercise period for warrants TO5 in Dicot starts today
Wed, Nov 01, 2023 08:00 CET Report this content
Press release: Uppsala, Sweden, November 1, 2023. Today, November 1, 2023, the exercise period for warrants of series TO5 in Dicot AB... |
| Oct 31, 2023 | Dicot AB presents Interim report Q3 2023 | Dicot AB presents Interim report Q3 2023
Tue, Oct 31, 2023 08:30 CET Report this content
Press release: Uppsala, Sweden, October 31, 2023. Dicot AB (publ) publishes the interim report for the period January-September 2023. The report is ava... |
| Oct 31, 2023 | Dicot AB presents Interim report Q3 2023 | Dicot AB presents Interim report Q3 2023
Tue, Oct 31, 2023 08:30 CET Report this content
Press release: Uppsala, Sweden, October 31, 2023. Dicot AB (publ) publishes the interim report for the period January-September 2023. The report is ava... |
| Oct 30, 2023 | The exercise price for warrants TO5 in Dicot has been set to SEK 0.086. The subscription period starts on November 1, 2023 | The exercise price for warrants TO5 in Dicot has been set to SEK 0.086. The subscription period starts on November 1, 2023
Mon, Oct 30, 2023 08:00 CET Report this content
Press release: Uppsala, Sweden, October 30, 2023. Dicot AB (publ) com... |
| Oct 30, 2023 | The exercise price for warrants TO5 in Dicot has been set to SEK 0.086. The subscription period starts on November 1, 2023 | The exercise price for warrants TO5 in Dicot has been set to SEK 0.086. The subscription period starts on November 1, 2023
Mon, Oct 30, 2023 08:00 CET Report this content
Press release: Uppsala, Sweden, October 30, 2023. Dicot AB (publ) com... |
| Oct 26, 2023 | The Nomination committee for Dicot AB appointed | The Nomination committee for Dicot AB appointed
Thu, Oct 26, 2023 16:45 CET Report this content
Press release: Uppsala, October 26, 2023. According to decision at the Annual General Meeting of Dicot AB on May 23, 2023, the Nomination commit... |
| Oct 26, 2023 | The Nomination committee for Dicot AB appointed | The Nomination committee for Dicot AB appointed
Thu, Oct 26, 2023 16:45 CET Report this content
Press release: Uppsala, October 26, 2023. According to decision at the Annual General Meeting of Dicot AB on May 23, 2023, the Nomination commit... |
| Oct 20, 2023 | The second part of Dicot's phase 1 study starts today | The second part of Dicot's phase 1 study starts today
Fri, Oct 20, 2023 08:00 CET Report this content
Press release: Uppsala, Sweden, October 20, 2023. In August, the pharmaceutical company Dicot's phase 1 study was initiated, with single d... |
| Oct 10, 2023 | Expert in sexual medicine presents Dicot's research results at American congress | Expert in sexual medicine presents Dicot's research results at American congress
Tue, Oct 10, 2023 10:30 CET Report this content
Press release: Uppsala, Sweden, October 10, 2023. The Sexual Medicine Society North America has selected the ph... |
| Sep 26, 2023 | Dicot applies for international patent protection | Dicot applies for international patent protection
Tue, Sep 26, 2023 10:15 CET Report this content
Uppsala, September 26, 2023. Pharmaceutical company Dicot has submitted an international patent application via the Patent Cooperation Treaty,... |
| Sep 4, 2023 | First participants dosed in Dicot's phase 1 trial | First participants dosed in Dicot's phase 1 trial
Mon, Sep 04, 2023 10:37 CET Report this content
Press release: Uppsala, September 4, 2023. The potency drug developer Dicot announces today that the first study participants have been dosed ... |
| Aug 29, 2023 | Dicot applies for US patent | Dicot applies for US patent
Tue, Aug 29, 2023 10:30 CET Report this content
Uppsala, August 29, 2023. The pharmaceutical company Dicot announces that a patent application has been submitted to the US Patent Office. The application covers th... |
| Aug 25, 2023 | Dicot's clinical phase 1 study starts today | Dicot's clinical phase 1 study starts today
Fri, Aug 25, 2023 08:50 CET Report this content
Press release: Uppsala, August 25, 2023. Today is the formal start of Dicot's clinical phase 1 study with the drug candidate LIB-01 as the first scr... |
| Aug 24, 2023 | Dicot AB presents Interim report Q2 2023 | Dicot AB presents Interim report Q2 2023
Thu, Aug 24, 2023 08:59 CET Report this content
Press release: Uppsala, Sweden, August 24, 2023. Dicot AB (publ) publishes the interim report for the period January-June 2023. The report is available... |
| Aug 15, 2023 | Dicot has received approval to start phase 1 clinical trial | Dicot has received approval to start phase 1 clinical trial
Tue, Aug 15, 2023 08:20 CET Report this content
Press release: Uppsala, August 15, 2023. Dicot announces that the Swedish Medical Products Agency has granted permission to start cl... |
| Aug 15, 2023 | Dicot has received approval to start phase 1 clinical trial | Dicot has received approval to start phase 1 clinical trial
Tue, Aug 15, 2023 08:20 CET Report this content
Press release: Uppsala, August 15, 2023. Dicot announces that the Swedish Medical Products Agency has granted permission to start cl... |
| Aug 14, 2023 | Dicot confirms planned start date in August for its phase 1 study | Dicot confirms planned start date in August for its phase 1 study
Mon, Aug 14, 2023 09:38 CET Report this content
Press release: Uppsala, August 14, 2023. The potency drug developer Dicot announces that the decision from the Swedish Medical... |
| Aug 14, 2023 | Dicot confirms planned start date in August for its phase 1 study | Dicot confirms planned start date in August for its phase 1 study
Mon, Aug 14, 2023 09:38 CET Report this content
Press release: Uppsala, August 14, 2023. The potency drug developer Dicot announces that the decision from the Swedish Medical... |
| Jun 29, 2023 | Swedish Startup Dicot Lands 250,000 SEK Grant to Propel Novel Lifestyle Drug Discovery | Key Takeaways
Uppsala-based startup Dicot receives 250,000 SEK in a grant round led by Almi Invest.
The pharmaceutical company focuses on the development of novel lifestyle drugs.
This is Dicot’s first funding round, boosting its total fund... |
| Jun 29, 2023 | Dicot is granted funds from Almi | Dicot is granted funds from Almi
Thu, Jun 29, 2023 08:31 CET Report this content
Pressrelease: Uppsala, Sweden, June 29, 2023. Dicot has been granted funds from Almi Uppsala equivalent to €22,000 to support the company's internationalizatio... |
| Jun 29, 2023 | Dicot is granted funds from Almi | Dicot is granted funds from Almi
Thu, Jun 29, 2023 08:31 CET Report this content
Pressrelease: Uppsala, Sweden, June 29, 2023. Dicot has been granted funds from Almi Uppsala equivalent to €22,000 to support the company's internationalizatio... |
| Jun 19, 2023 | Dicot AB receives SEK 20.7 million through the warrants of series TO4 with a 83.3% subscription rate | Dicot AB receives SEK 20.7 million through the warrants of series TO4 with a 83.3% subscription rate
Mon, Jun 19, 2023 15:10 CET Report this content
Press release: Uppsala, Sweden, June 19, 2023.
Dicot AB (publ) announces the outcome regard... |
| Jun 19, 2023 | Dicot AB receives SEK 20.7 million through the warrants of series TO4 with a 83.3% subscription rate | Dicot AB receives SEK 20.7 million through the warrants of series TO4 with a 83.3% subscription rate
Mon, Jun 19, 2023 15:10 CET Report this content
Press release: Uppsala, Sweden, June 19, 2023.
Dicot AB (publ) announces the outcome regard... |
| Jun 5, 2023 | Dicot enters commitment agreement regarding the company´s warrants of series TO4 and thereby secures additional SEK 13.4 million | Dicot enters commitment agreement regarding the company´s warrants of series TO4 and thereby secures additional SEK 13.4 million
Mon, Jun 05, 2023 11:58 CET Report this content
Press Release: Uppsala, Sweden, June 5, 2023. Dicot AB (publ) h... |
| Jun 5, 2023 | Dicot enters commitment agreement regarding the company´s warrants of series TO4 and thereby secures additional SEK 13.4 million | Dicot enters commitment agreement regarding the company´s warrants of series TO4 and thereby secures additional SEK 13.4 million
Mon, Jun 05, 2023 11:58 CET Report this content
Press Release: Uppsala, Sweden, June 5, 2023. Dicot AB (publ) h... |
| Jun 1, 2023 | The exercise period for warrants of series TO4 in Dicot starts today | The exercise period for warrants of series TO4 in Dicot starts today
Thu, Jun 01, 2023 08:50 CET Report this content
Press release: Uppsala, Sweden, June 1, 2023. Today, June 1, 2023, the exercise period for warrants of series TO4 in Dicot ... |
| Jun 1, 2023 | The exercise period for warrants of series TO4 in Dicot starts today | The exercise period for warrants of series TO4 in Dicot starts today
Thu, Jun 01, 2023 08:50 CET Report this content
Press release: Uppsala, Sweden, June 1, 2023. Today, June 1, 2023, the exercise period for warrants of series TO4 in Dicot ... |
| Jun 1, 2023 | Dicot has submitted application to start clinical phase 1 trial | Dicot has submitted application to start clinical phase 1 trial
Thu, Jun 01, 2023 10:15 CET Report this content
Press release: Uppsala, June 1, 2023. Dicot announces today that an application to start clinical trial with the potency drug ca... |
| Jun 1, 2023 | Dicot has submitted application to start clinical phase 1 trial | Dicot has submitted application to start clinical phase 1 trial
Thu, Jun 01, 2023 10:15 CET Report this content
Press release: Uppsala, June 1, 2023. Dicot announces today that an application to start clinical trial with the potency drug ca... |
| May 31, 2023 | Success in Dicot´s test of alternative production technique | Success in Dicot´s test of alternative production technique
Wed, May 31, 2023 13:46 CET Report this content
Press release: Uppsala, May 31, 2023. In collaboration with Uppsala University and W. Szafer Institute of Botany, Dicot has investig... |
| May 31, 2023 | Major shareholders, board members, and senior executives have committed to exercise TO4 warrants in Dicot, corresponding to 3.9 million SEK | Major shareholders, board members, and senior executives have committed to exercise TO4 warrants in Dicot, corresponding to 3.9 million SEK
Wed, May 31, 2023 13:17 CET Report this content
Press release: Uppsala, Sweden, May 31, 2023. Dicot ... |
| May 31, 2023 | Success in Dicot´s test of alternative production technique | Success in Dicot´s test of alternative production technique
Wed, May 31, 2023 13:46 CET Report this content
Press release: Uppsala, May 31, 2023. In collaboration with Uppsala University and W. Szafer Institute of Botany, Dicot has investig... |
| May 31, 2023 | Major shareholders, board members, and senior executives have committed to exercise TO4 warrants in Dicot, corresponding to 3.9 million SEK | Major shareholders, board members, and senior executives have committed to exercise TO4 warrants in Dicot, corresponding to 3.9 million SEK
Wed, May 31, 2023 13:17 CET Report this content
Press release: Uppsala, Sweden, May 31, 2023. Dicot ... |
| May 30, 2023 | The exercise price for the warrants of series TO4 in Dicot has been determined and the subscription period starts on June 1, 2023 | The exercise price for the warrants of series TO4 in Dicot has been determined and the subscription period starts on June 1, 2023
Tue, May 30, 2023 08:28 CET Report this content
Press release: Uppsala, Sweden, May 30, 2023. Dicot AB (publ) ... |
| May 30, 2023 | The exercise price for the warrants of series TO4 in Dicot has been determined and the subscription period starts on June 1, 2023 | The exercise price for the warrants of series TO4 in Dicot has been determined and the subscription period starts on June 1, 2023
Tue, May 30, 2023 08:28 CET Report this content
Press release: Uppsala, Sweden, May 30, 2023. Dicot AB (publ) ... |
| May 29, 2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!
Mon, May 29, 2023 09:45 CET Report this content
It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| May 19, 2023 | Dicot AB presents Interim report January - March 2023 | Dicot AB presents Interim report January - March 2023
Fri, May 19, 2023 11:40 CET Report this content
Press release: Uppsala, Sweden, May 19, 2023. Dicot AB (publ) publishes the interim report for the period January - March 2023. The report... |
| May 19, 2023 | Dicot AB presents Interim report January - March 2023 | Dicot AB presents Interim report January - March 2023
Fri, May 19, 2023 11:40 CET Report this content
Press release: Uppsala, Sweden, May 19, 2023. Dicot AB (publ) publishes the interim report for the period January - March 2023. The report... |
| May 17, 2023 | Dicot's study drug has arrived in Sweden | Dicot's study drug has arrived in Sweden
Wed, May 17, 2023 08:45 CET Report this content
Press release: Uppsala, May 17, 2023. In preparation for Dicot's phase 1 clinical trial, the study drug to be used has now been manufactured by Thermo ... |
| May 17, 2023 | Dicot's study drug has arrived in Sweden | Dicot's study drug has arrived in Sweden
Wed, May 17, 2023 08:45 CET Report this content
Press release: Uppsala, May 17, 2023. In preparation for Dicot's phase 1 clinical trial, the study drug to be used has now been manufactured by Thermo ... |
| May 3, 2023 | Dicot recruits Mats Silvander as CTO | Dicot recruits Mats Silvander as CTO
Wed, May 03, 2023 11:30 CET Report this content
Press release: Uppsala, May 3, 2023. Mats Silvander, PhD, has been recruited as Chief Technical Officer at the pharmaceutical company Dicot and will lead a... |
| May 3, 2023 | Dicot recruits Mats Silvander as CTO | Dicot recruits Mats Silvander as CTO
Wed, May 03, 2023 11:30 CET Report this content
Press release: Uppsala, May 3, 2023. Mats Silvander, PhD, has been recruited as Chief Technical Officer at the pharmaceutical company Dicot and will lead a... |
| May 2, 2023 | Start of Dicot's phase 1 trial booked for August | Start of Dicot's phase 1 trial booked for August
Tue, May 02, 2023 10:30 CET Report this content
Press release: Uppsala, May 2, 2023. Dicot's development of its potency drug candidate LIB-01 is proceeding according to plan and the company h... |
| May 2, 2023 | Start of Dicot's phase 1 trial booked for August | Start of Dicot's phase 1 trial booked for August
Tue, May 02, 2023 10:30 CET Report this content
Press release: Uppsala, May 2, 2023. Dicot's development of its potency drug candidate LIB-01 is proceeding according to plan and the company h... |
| Apr 28, 2023 | Dicot AB publishes the Annual Report 2022 | Dicot AB publishes the Annual Report 2022
Fri, Apr 28, 2023 08:30 CET Report this content
Press release: Uppsala, Sweden, April 28, 2023. The annual report of Dicot AB (publ) for 2022 has been published today and is available on www.dicot.s... |
| Apr 28, 2023 | Dicot AB publishes the Annual Report 2022 | Dicot AB publishes the Annual Report 2022
Fri, Apr 28, 2023 08:30 CET Report this content
Press release: Uppsala, Sweden, April 28, 2023. The annual report of Dicot AB (publ) for 2022 has been published today and is available on www.dicot.s... |
| Apr 27, 2023 | Dicot's toxicology program successfully completed | Dicot's toxicology program successfully completed
Thu, Apr 27, 2023 11:00 CET Report this content
Press release: Uppsala, April 27, 2023. Dicot announces today that the preclinical toxicology program required to start clinical phase 1 trial... |
| Apr 27, 2023 | Dicot's toxicology program successfully completed | Dicot's toxicology program successfully completed
Thu, Apr 27, 2023 11:00 CET Report this content
Press release: Uppsala, April 27, 2023. Dicot announces today that the preclinical toxicology program required to start clinical phase 1 trial... |
| Apr 4, 2023 | Dicot’s nomination committee proposes Jan-Eric Österlund as new board member | Dicot’s nomination committee proposes Jan-Eric Österlund as new board member
Tue, Apr 04, 2023 15:15 CET Report this content
Press release: Uppsala, Sweden, April 4, 2023. The Nomination Committee of Dicot AB proposes that Jan-Eric Österlun... |
| Mar 28, 2023 | Successful meeting with Swedish MPA strengthens Dicot's clinical trial application | Successful meeting with Swedish MPA strengthens Dicot's clinical trial application
Tue, Mar 28, 2023 10:00 CET Report this content
Uppsala, March 28, 2023. Dicot has now conducted the last of two planned regulatory meetings prior to an appl... |
| Mar 8, 2023 | Dicot contracts world leading medical expert within erectile dysfunction | Dicot contracts world leading medical expert within erectile dysfunction
Wed, Mar 08, 2023 13:00 CET Report this content
Press release: Uppsala, Sweden, March 8, 2023. Dicot has entered into a consultancy agreement with medical doctor Harin... |
| Feb 27, 2023 | Dicot AB presents Year-End Report 2022 | Dicot AB presents Year-End Report 2022
Mon, Feb 27, 2023 10:46 CET Report this content
Press release: Uppsala, February 27, 2023. Dicot AB (publ) hereby publishes its year-end report for the period January - December 2022 and for the fourth... |
| Feb 20, 2023 | Dicot has started manufacturing of the study drug for clinical trials in line with the schedule | Dicot has started manufacturing of the study drug for clinical trials in line with the schedule
Mon, Feb 20, 2023 13:47 CET Report this content
Press release: Uppsala, February 20, 2023. Dicot announces that the GMP manufacturing of the stu... |
| Feb 17, 2023 | Dicot's study results presented today at European Society for Sexual Medicine | Dicot's study results presented today at European Society for Sexual Medicine
Fri, Feb 17, 2023 12:16 CET Report this content
Uppsala, February 17, 2023. Today the pharmaceutical company Dicot presented the latest study of the mechanism of ... |
| Jan 23, 2023 | Dicot moves forward with a new patent application | Dicot moves forward with a new patent application
Mon, Jan 23, 2023 10:30 CET Report this content
Uppsala, January 23, 2023. The pharmaceutical company Dicot AB that develops LIB-01 to become a new potency drug, today announces that it is m... |
| Jan 19, 2023 | Dicot has contracted Thermo Fisher Scientific for manufacturing of LIB-01 | Dicot has contracted Thermo Fisher Scientific for manufacturing of LIB-01
Thu, Jan 19, 2023 10:00 CET Report this content
Press release: Uppsala, January 19, 2023. The pharmaceutical company Dicot has contracted Thermo Fisher Scientific, th... |
| Jan 4, 2023 | Procurement completed for Dicot's phase 1 studies | Procurement completed for Dicot's phase 1 studies
Wed, Jan 04, 2023 09:30 CET Report this content
Uppsala, January 4, 2023. The pharmaceutical company Dicot announces the contracting of reputable Clinical Trial Consultants AB (CTC) for cond... |
| Dec 8, 2022 | Dicot's study results selected for presentation at European Society for Sexual Medicine | Dicot's study results selected for presentation at European Society for Sexual Medicine
Thu, Dec 08, 2022 13:00 CET Report this content
Uppsala, December 8, 2022. The pharmaceutical company Dicot announces that results from the latest study... |
| Nov 15, 2022 | New study: LIB-01 assumed to be the next generation of potency drugs | New study: LIB-01 assumed to be the next generation of potency drugs
Tue, Nov 15, 2022 13:57 CET Report this content
Uppsala, November 15, 2022. Dicot's latest study of the mechanism of action of LIB-01, i.e., how the drug affects the body ... |
| Nov 14, 2022 | Successful first regulatory meeting for LIB-01 | Successful first regulatory meeting for LIB-01
Mon, Nov 14, 2022 15:45 CET Report this content
Uppsala, November 14, 2022. Dicot announces today that the first regulatory meeting for LIB-01 prior to an application to start clinical trials h... |
| Nov 3, 2022 | The Nomination committee for Dicot AB appointed | The Nomination committee for Dicot AB appointed
Thu, Nov 03, 2022 10:30 CET Report this content
Press release: Uppsala, November 3, 2022. According to decision at the Annual General Meeting of Dicot AB on May 24, 2022, the Nomination commit... |
| Nov 1, 2022 | Interim Report January–September 2022, Dicot AB | Interim Report January–September 2022, Dicot AB
Tue, Nov 01, 2022 08:30 CET Report this content
Press release: Uppsala, November 1, 2022. A summary of the Interim report January – September 2022, for Dicot AB (publ) is now available on the ... |
| Nov 1, 2022 | Correction: Interim Report January–September 2022, Dicot AB | Correction: Interim Report January–September 2022, Dicot AB
Tue, Nov 01, 2022 11:03 CET Report this content
Press release: Uppsala, November 1, 2022. The correction is to inform that the previous press release regarding Dicot AB's (publ) in... |
| Sep 7, 2022 | The European Commission has selected Dicot to compete in the Innovation Radar Prize | The European Commission has selected Dicot to compete in the Innovation Radar Prize
Wed, Sep 07, 2022 09:30 CET Report this content
Uppsala, September 7, 2022. The European Commission has selected Dicot from thousands of small and medium-si... |
| Aug 25, 2022 | Interim Report January – June 2022, Dicot AB | Interim Report January – June 2022, Dicot AB
Thu, Aug 25, 2022 09:20 CET Report this content
Press release: Uppsala, August 25, 2022. A summary of the Interim report January – June 2022, for Dicot AB (publ) is now available on the company w... |
| Jun 29, 2022 | Dicot demonstrates good results in new efficacy study | Dicot demonstrates good results in new efficacy study
Wed, Jun 29, 2022 14:30 CET Report this content
Press release: Uppsala, June 29, 2022. Dicot AB is developing a new potency drug aiming at becoming the first choice of treatment. The com... |
| Jun 17, 2022 | Dicot AB receives approximately 10 MSEK through the warrants of series TO 3 with a 90% subscription rate | Dicot AB receives approximately 10 MSEK through the warrants of series TO 3 with a 90% subscription rate
Fri, Jun 17, 2022 18:35 CET Report this content
Press release: Uppsala, June 17, 2022.
Dicot AB (publ) (”Dicot” or the ”Company”) annou... |
| Jun 13, 2022 | Members of Dicot's board and management strengthen their shareholding | Members of Dicot's board and management strengthen their shareholding
Mon, Jun 13, 2022 15:43 CET Report this content
Press release: Uppsala, June 13, 2022. The company announces that members in the board and management are increasing their... |
| Jun 13, 2022 | Last day of trading with the warrants of series TO 3 in Dicot | Last day of trading with the warrants of series TO 3 in Dicot
Mon, Jun 13, 2022 08:30 CET Report this content
Press release: Uppsala, June 13, 2022.
Today, June 13, 2022, is the last day of trading with the warrants of series TO 3. The subs... |
| Jun 10, 2022 | Dicot moves forward with a new patent application | Dicot moves forward with a new patent application
Fri, Jun 10, 2022 09:45 CET Report this content
Press release: Uppsala, June 10, 2022. Dicot AB is developing the drug candidate LIB-01, a potency drug to better treat erectile dysfunction a... |
| Jun 9, 2022 | Dicot presents at Småbolagsdagarna, Monday June 13 | Dicot presents at Småbolagsdagarna, Monday June 13
Thu, Jun 09, 2022 10:50 CET Report this content
Press release: Uppsala, June 9, 2022. Meet Dicot's CEO Elin Trampe at Småbolagsdagarna on Monday June 13 when she presents the company's deve... |
| Jun 1, 2022 | The subscription period for warrants of series TO 3 in Dicot begins today | The subscription period for warrants of series TO 3 in Dicot begins today
Wed, Jun 01, 2022 08:30 CET Report this content
Press release: Uppsala, June 1, 2022.
Today on June 1, 2022, the subscription period for the warrants of series TO 3 i... |
| May 31, 2022 | Dicot AB enters research collaboration with Uppsala University and the W. Szafer Institute of Botany | Dicot AB enters research collaboration with Uppsala University and the W. Szafer Institute of Botany
Tue, May 31, 2022 13:00 CET Report this content
Press release: Uppsala, May 31, 2022. Dicot AB is developing the drug candidate LIB-01, whi... |
| May 6, 2022 | Summary of Interim Report January – March 2022, Dicot AB | Summary of Interim Report January – March 2022, Dicot AB
Fri, May 06, 2022 12:30 CET Report this content
Press release: Uppsala, May 6, 2022. A summary of the Interim report January – March 2022, for Dicot AB (publ) is now available on the ... |
| May 5, 2022 | Dicot's CEO to present at Naventus Healthcare Summit on May 10 | Dicot's CEO to present at Naventus Healthcare Summit on May 10
Thu, May 05, 2022 11:30 CET Report this content
Press release: Uppsala, May 5, 2022. On Tuesday May 10 at 14:25, Dicot's CEO Elin Trampe will present the company at the Naventus... |
| Apr 29, 2022 | Dicot presenting on Aktiedagen in Stockholm | Dicot presenting on Aktiedagen in Stockholm
Fri, Apr 29, 2022 10:00 CET Report this content
Press release: Uppsala, April 29, 2022. On Monday May 2, CEO Elin Trampe will be on the Opera Terrace stage presenting Dicot during the event Aktied... |
| Apr 19, 2022 | Charlotta Gauffin PhD is the new Chief Scientific Officer at Dicot | Charlotta Gauffin PhD is the new Chief Scientific Officer at Dicot
Tue, Apr 19, 2022 14:00 CET Report this content
Press release: Uppsala, April 19, 2022. Charlotta Gauffin PhD has been hired as Chief Scientific Officer at Dicot starting Ju... |
| Apr 7, 2022 | Dicot's nomination committee proposes Fredrik Buch and Michael Zell as new Board members | Dicot's nomination committee proposes Fredrik Buch and Michael Zell as new Board members
Thu, Apr 07, 2022 13:00 CET Report this content
Press release: Uppsala, April 7, 2022. The Nomination Committee of Dicot AB proposes that Fredrik Buch ... |
| Apr 6, 2022 | Dicot to develop LIB-01 to an oral drug | Dicot to develop LIB-01 to an oral drug
Wed, Apr 06, 2022 10:00 CET Report this content
Press release: Uppsala, April 6, 2022. Dicot announces that after evaluating two formulation alternatives, the company decides to prioritize the develop... |
| Apr 1, 2022 | Elin Trampe takes over as CEO of Dicot AB | Elin Trampe takes over as CEO of Dicot AB
Fri, Apr 01, 2022 09:30 CET Report this content
Press release: Uppsala, April 1, 2022. Elin Trampe is the new CEO of the pharmaceutical company Dicot starting today. Elin brings important experience... |